Learn how innovative bispecific antibody therapy treatment works through the FCS’s bispecific maintenance program and how it helps the immune system better recognize and attack cancer cells.
Learn the basics of bispecific antibody therapy and what patients can expect during step-up dosing treatment at Florida Cancer Specialists & Research Institute.
Florida Cancer Specialists & Research Institute leaders present specialty pharmacy operations, dispensing and patient navigation best practices at the NCODA 2026 Spring Forum, highlighting innovations that improve access, patient experience and clinical outcomes in oncology care.
Bispecific Therapy MaintenanceLearn how innovative bispecific antibody therapy treatment works through the FCS’s bispecific maintenance program and how it helps the immune system better recognize and attack cancer cells.
FCS Highlights Leadership in Advancing Medically Integrated Oncology CareFlorida Cancer Specialists & Research Institute leaders present specialty pharmacy operations, dispensing and patient navigation best practices at the NCODA 2026 Spring Forum, highlighting innovations that improve access, patient experience and clinical outcomes in oncology care.
Radiation Therapy for Plantar FasciitisDiscover how low-dose radiation therapy offers a non-surgical option for chronic plantar fasciitis that hasn’t improved with conservative care.
FCS Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian CancerFDA approves KEYTRUDA for certain hard-to-treat ovarian cancers, with research support from FCS improving outcomes.
FCS Joins Oncology Leaders to Help Shape the Future of Cancer Care at FLASCO 2026FCS joins oncology leaders at FLASCO 2026 to share insights on workforce transformation and innovative care models shaping the future of cancer care.
FCS Phase 3 Trial Demonstrates Initial Clinical Benefit of Novel Immunotherapy For Advanced Non-Small Cell Lung CancerFCS contributes to PRESERVE-003 findings showing gotistobart may improve outcomes in metastatic NSCLC.
FCS Contributes to Phase 1 Study Demonstrating Antitumor Activity with First-in-Class KRAS-Targeted Therapy for Treatment of Lung and Pancreatic CancersFCS participates in study for a targeted therapy for the treatment of two cancers